BridgeBio Pharma: Turning translational academic research into medicines for patients with genetic diseases
BridgeBio is a pharmaceutical company that finds, develops and delivers breakthrough medicines for genetic diseases. Founded in 2015 by a team of industry veterans, the company has built a portfolio of over 30 development programs ranging from discovery to Phase 3 clinical trials with two approved products. The company’s therapeutic areas include genetic dermatology, oncology, cardiology, neurology and endocrinology.

BridgeBio continues to search for new innovations originating in academia that can be translated into breakthrough therapies for genetic diseases and cancers with clear genetic drivers. BridgeBio is excited to introduce their partnering model to researchers at the University of Oxford as part of this seminar series. Please join us for a brief presentation, which will provide additional information regarding the company’s areas of interest, showcase some of their success stories and answer questions about how the company collaborates with its academic partners.
Date: 1 February 2022, 12:00 (Tuesday, 3rd week, Hilary 2022)
Venue: Zoom
Speaker: Dr Anna Hakes (BridgeBio)
Organising department: Medical Sciences Office
Organisers: Sheena Lee (MSD Business Partnerships Office), Medical Sciences Division Business Partnerships Office (University of Oxford)
Organiser contact email address:
Host: David Bowkett (University of Oxford)
Part of: Industry Insight Seminar Series
Booking required?: Required
Booking url:
Cost: Free
Audience: Members of the University of Oxford and the Biotech/Pharma industry
Editor: Sheena Lee